Patients' Perceptions of Fatigue in Response to Biochemotherapy for Metastatic Melanoma: A Preliminary Study

Mei Rosemary Fu

Clay M. Anderson

Roxanne W. McDaniel

Jane Armer

ONF 2002, 29(6), 961-966. DOI: 10.1188/02.ONF.961-966

Purpose/Objectives: To explore patients' perceptions of fatigue in response to biochemotherapy treatment for metastatic melanoma.

Design: A descriptive-correlational, cross-sectional study.

Setting: A cancer center in the midwestern United States.

Sample: 12 adult patients between the ages of 28-70 who received at least one cycle of biochemotherapy treatment for metastatic melanoma (stages III and IV) from the inpa-tient or outpatient services of a midwestern cancer center.

Methods: A demographic data sheet and the Revised Piper Fatigue Scale (PFS) were used to collect data at a single point in time after patients received at least one cycle of biochemotherapy.

Findings: The majority of patients who received biochemotherapy reported severe or moderate fatigue. Female patients' total fatigue scores were higher than those of male patients. Fatigue duration varied from hours to months, with a maximum duration of 12 months after biochemotherapy treatment. All of the patients reported that the most direct causes of their fatigue were metastatic melanoma and biochemotherapy treatment.

Conclusions: Patients who received biochemotherapy treatment for metastatic melanoma reported moderate to severe fatigue. Female patients experienced more intense fatigue than male patients. The findings also supported the multidimensionality of fatigue construct identified in prior fatigue studies. The four dimensions/subscales of fatigue assessed by the Revised PFS were highly correlated to total fatigue scores.

Implications for Nursing: Biochemotherapy is a newer treatment modality for metastatic melanoma. Fatigue, one of the severe toxicities from biochemotherapy treatment, necessitates attention from nurses. The findings will assist nurses in teaching patients about fatigue that may be expected during or after biochemotherapy and about self-care strategies to manage fatigue.

Jump to a section

    References

    Aaronson, L.S., Teel, C.S., Cassmeyer, V., Neuberger, G.B., Pallikkathayil, L., Pierce, J., et al. (1999). Defining and measuring fatigue. Image-The Journal of Nursing Scholarship, 31, 45-50.

    Aistars, J. (1987). Fatigue in the cancer patient: A conceptual approach to a clinical problem. Oncology Nursing Forum, 14(6), 25-30.

    American Cancer Society. (2002). Cancer facts and figures. Atlanta, GA: Author.

    Anderson, C.M., Buzaid, A.C., Ali-Osman, F., Braunschweiger, P.G., & Grimm, E.A. (1997). Biochemotherapy in the treatment of advanced melanoma: Clinical results and potential mechanisms of anticancer activity. In D. Khayat & G.N. Hortabagyi (Eds.), Progress in anticancer chemotherapy, Vol. 1 (pp. 68-87). Cambridge, MA: Blackwell Science.

    Anderson, C.M., Buzaid, A.C., & Legha, S.S. (1995). Systemic treatments for advanced cutaneous melanoma. Oncology, 9, 1149-1158.

    Anderson, C.M., Buzaid, A.C., Sussman, J., Lee, J.J., Ali-Osman, F., Braunschweiger, P.G., et al. (1998). Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Research, 8, 149-155.

    Atkins, M.B., Lotze, M.T., Dutcher, J.P., Fisher, R.I., Weiss, G., Margolin, K., et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology, 17, 2105-2116.

    Berger, A.M. (1998). Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncology Nursing Forum, 25, 51-62.

    Berger, A.M., & Higginbotham, P. (2000). Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. Oncology Nursing Forum, 27, 1443-1448.

    Cohen, G.L., & Falkson, C.I. (1998). Current treatment options for malignant melanoma. Drugs, 55, 791-799.

    Crosby, L.J. (1991). Factors which contribute to fatigue associated with rheumatoid arthritis. Journal of Advanced Nursing, 16, 974-981.

    Dalakas, M.C., Mock, V., & Hawkins, M.J. (1998). Fatigue: Definitions, mechanisms, and paradigms for study. Seminars in Oncology, 25(Suppl. 1), 48-53.

    Frank-Stromborg, M. (1986). Health promotion behaviors in ambulatory cancer patients: Facts or fiction? Oncology Nursing Forum, 13(4), 37-13.

    Fu, M., LeMone, P., McDanel, R., & Bausler, C. (2001). A multivariate validation of the defining characteristics of fatigue. Nursing Diagnosis: International Journal of Nursing Language and Classification, 12, 15-27.

    Graydon, J.E., Bubela, N., Irvine, D., & Vincent, L. (1995). Fatigue-reducing strategies used by patients receiving treatment for cancer. Cancer Nursing, 18, 23-28.

    Haigh, P.I., Difronzo, L.A., Gammon, G., & Morton, D.L. (1999). Vaccine therapy for patients with melanoma. Oncology, 13, 1561-1574.

    Holley, S.K. (2000). Evaluating patient distress from cancer-related fatigue: An instrument development study. Oncology Nursing Forum, 27, 1425-1431.

    Legha, S.S., Ring, S., Bedikian, A., Plager, C., Eton, O., Buzaid, A.C., et al. (1996). Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Annals of Oncology, 7, 727-835.

    Legha, S.S., Ring, S., Eton, O., Bedikian, A., Buzaid, A.C., Plager, C., et al. (1998). Development of a biochemotherapy regiment with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. Journal of Clinical Oncology, 16, 1752-1759.

    Legha, S.S., Ring, S., Eton, O., Bedikian, A., Plager, C., & Papadopoulos, N. (1997). Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center experience. Cancer Journal from Scientific American, (3 Suppl. 1), S9-S15.

    Mac Vicar, M.G., Winningham, M.L., & Nickel, J.L. (1989). Effects of aerobic interval training on cancer patients' functional capacity. Nursing Research, 38, 348-351.

    North American Nursing Diagnosis Association (NANDA). (2001). NANDA nursing diagnosis: Definitions and classification 2001-2002. Philadelphia: Author.

    Orem, D.E. (1995). Nursing: Concepts of practice (5th ed.). St. Louis, MO: Mosby-Year Book.

    Piper, B.F. (1997). Measuring fatigue. In M. Frank-Stromborg & S.J. Olsen (Eds.), Instruments for clinical health-care research (2nd ed., pp. 482-496). Boston: Jones and Bartlett.

    Piper, B.F., Dibble, S.L., Dodd, M.J., Weiss, M.C., Slaughter, R.E., & Paul, S.M. (1998). The revised Piper Fatigue Scale: Psychometric evaluation in women with breast cancer. Oncology Nursing Forum, 25, 677-684.

    Piper, B.F., Lindsey, A.M., & Dodd, M.J. (1987). Fatigue mechanisms in cancer patients: Developing nursing theory. Oncology Nursing Forum, 14(6), 17-23.

    Piper, B.F., Lindsey, A.M., Dodd, M.J., Ferketich, S., Paul, S. M., & Weller, S. (1989). The development of an instrument to measure the subjective dimension of fatigue. In S.G. Funk, E.M. Tornquist, M.T. Champagne, L.A. Gopp, & R.A. Wiese (Eds.), Key aspects of comfort: Management of pain, fatigue, and nausea (pp. 199-208). New York: Springer.

    Piper, B.F., Rieger, P.T., Brophy, L., Haeuber, D., Hood, L.E., Lyver, A., et al. (1989). Recent advances in the management of biotherapy-related side effects: Fatigue. Oncology Nursing Forum, 16(Suppl. 6), 27-34.

    Ream, E., & Richardson, A. (1996). Fatigue: A concept analysis. International Journal of Nursing Studies, 33, 519-529.

    Richardson, A., & Ream, E.K. (1997). Self-care behaviours initiated by chemotherapy patients in response to fatigue. International Journal of Nursing Studies, 34, 35-43.

    Robinson, K.D., & Posner, J.D. (1992). Patterns of self-care needs and interventions related to biologic response modifier therapy: Fatigue as a model. Seminars in Oncology Nursing, 8(4 Suppl. 1), 17-22.

    Schwartz, A. (1998). The Schwartz Cancer Fatigue Scale: Testing reliability and validity. Oncology Nursing Forum, 25, 711-717.

    Schwartz, J.E., Jandorf, L., & Krupp, L.B. (1993). The measurement of fatigue: A new instrument. Journal of Psychosomatic Research, 37, 753-762.

    Tiesinga, L., Dassen, T.W, & Halfens, R.J. (1996). Fatigue: A summary of the definitions, dimensions, and indicators. Nursing Diagnosis, 7, 51-62.

    Winningham, M.L., Nail, L.M., Burke, M.B., Brophy, L., Cimprich, B., Jones, L.S., et al. (1994). Fatigue and the cancer experience: The state of the knowledge. Oncology Nursing Forum, 21, 23-36.